XERAXIS is a repurposed medicine that we are currently developing as a potential best-in-class, self-administered, once-daily, topical therapy for the treatment of primary axillary hyperhidrosis, or excessive underarm sweating.

A first-in-human phase I clinical study has been conducted in two parts: in part I, subjects were treated in an open-label design with three different dose levels of XERAXIS, applied to one or both axillae; in part II the same subjects were treated in randomized, double-blind, placebo-controlled design with one selected dose of XERAXIS for seven days applied to one axilla, versus vehicle (placebo) applied to the contralateral axilla. The study was conducted in compliance with current EU GCP regulations by a CRO in the Netherlands. Soon we hope to announce topline results from this first-in-human phase I clinical study for XERAXIS spray solution.